Abstract
The discovery of rifampicin in 1965 ushered in the era of short-course antituberculosis (TB) chemotherapy. The duration of anti-TB therapy was reduced from 12–24 months to 6 months. Thrombocytopenia is an uncommon but severe side effect of rifampicin, which needs a high clinical index of suspicion for diagnosis. It reverses completely on stopping the drug. Re-challenge is not advised because thrombocytopenia will recur on re-initiation of the drug. We present the case of a patient with rifampicin-induced thrombocytopenia who presented with purpuric rash all over the body. Investigations revealed a low platelet count which resolved completely on stopping the drug. This case highlights the importance of diagnosis of a rare adverse drug reaction and prompts management, which leads to a good outcome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
